Moderna

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. 

CEO
Stéphane Bancel
CEOStéphane Bancel
Employees
5,800
Employees5,800
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
5,800
Employees5,800

MRNA Key Statistics

Market cap
16.50B
Market cap16.50B
Price-Earnings ratio
-5.24
Price-Earnings ratio-5.24
Dividend yield
Dividend yield
Average volume
11.05M
Average volume11.05M
High today
$44.80
High today$44.80
Low today
$39.00
Low today$39.00
Open price
$41.85
Open price$41.85
Volume
16.34M
Volume16.34M
52 Week high
$55.20
52 Week high$55.20
52 Week low
$22.28
52 Week low$22.28

Stock Snapshot

As of today, Moderna(MRNA) shares are valued at $42.35. The company's market cap stands at 16.5B, with a P/E ratio of -5.24.

On 2026-02-15, Moderna(MRNA) stock traded between a low of $39.00 and a high of $44.80. Shares are currently priced at $42.35, which is +8.6% above the low and -5.5% below the high.

Moderna(MRNA) shares are trading with a volume of 16.34M, against a daily average of 11.05M.

In the last year, Moderna(MRNA) shares hit a 52-week high of $55.20 and a 52-week low of $22.28.

In the last year, Moderna(MRNA) shares hit a 52-week high of $55.20 and a 52-week low of $22.28.

MRNA News

Simply Wall St 2h
FDA Flu Ruling Tests Moderna Regulatory Assumptions And mRNA Pipeline Timing

FDA declined to review Moderna’s mRNA flu vaccine application, despite prior agreement on study design. The decision reportedly went against the recommendation...

FDA Flu Ruling Tests Moderna Regulatory Assumptions And mRNA Pipeline Timing
TipRanks 16h
Moderna Earnings Call: Cost Cuts, Cash, and Risk

Moderna ((MRNA)) has held its Q4 earnings call. Read on for the main highlights of the call. Valentine's Day Sale - 70% Off Unlock hedge fund-level data and pow...

TipRanks 2d
Moderna price target raised to $27 from $24 at BofA

BofA raised the firm’s price target on Moderna (MRNA) to $27 from $24 and keeps an Underperform rating on the shares. The company’s Q4 revenue came in slightly...

Analyst ratings

70%

of 27 ratings
Buy
14.8%
Hold
70.4%
Sell
14.8%

More MRNA News

Benzinga 2d
Moderna Promises Revenue Growth In 2026, Even As FDA Flu Vaccine Setback Looms

Moderna Inc. (NASDAQ:MRNA) on Friday reported a fourth-quarter loss of $2.11, beating the expected loss of $2.59, lower than a loss of $2.91 a year ago. The COV...

Moderna Promises Revenue Growth In 2026, Even As FDA Flu Vaccine Setback Looms
The Motley Fool 2d
Moderna Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. Feb. 13, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Stéphane Bancel President — Stephen Hoge Chief Financ...

Moderna Q4 2025 Earnings Call Transcript
Investor's Business Daily 2d
Moderna Pops On Fourth-Quarter Report, But Can It Overcome Recent FDA Setbacks?

Technology Moderna Pops On Fourth-Quarter Report, But Can It Overcome Recent FDA Setbacks? Licensing Moderna (MRNA) stock popped Friday after the company report...

Moderna Pops On Fourth-Quarter Report, But Can It Overcome Recent FDA Setbacks?
Nasdaq 2d
Moderna Q4 Loss Narrows

(RTTNews) - Moderna, Inc. (MRNA), a biotechnology company, Friday reported narrower loss for the fourth quarter compared to the same period last year. Quarterl...

Moderna Q4 Loss Narrows
24/7 Wall St. 2d
Moderna Just Crushed Estimates While Everyone Was Looking the Other Way

Moderna Just Crushed Estimates While Everyone Was Looking the Other Way Quick Read Moderna (MRNA) beat Q4 expectations with $678M revenue but total sales fell...

Moderna Just Crushed Estimates While Everyone Was Looking the Other Way
Sherwood News 2d
Moderna reports Q4 earnings beat, upbeat 2026 outlook

The report comes after Moderna said the FDA is refusing to consider an application for its mRNA flu vaccine. Moderna reported Q4 earnings results on Friday tha...

Moderna reports Q4 earnings beat, upbeat 2026 outlook
Simply Wall St 2d
Is Moderna Now Fairly Priced After Its Recent Share Price Rebound?

If you are wondering whether Moderna's current share price still reflects its long term potential or if the market has moved on, you are not alone. The stock c...

Is Moderna Now Fairly Priced After Its Recent Share Price Rebound?

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.